Scientific Online Resource System

Scripta Scientifica Medica

Transient parotitis in the course of clozapine treatment: a case report and review of the literature

Koraliya Todorova-Nenova

Abstract

Introduction: Clozapine is an atypical antipsychotic, treatment of choice for patients unresponsive to, or intolerant of other antipsychotic drugs. While most of the adverse effects of clozapine are well discussed in the literature, clozapine-induced parotitis emerges as an uncommon complication, which clinicians should be aware of.

Aim: The aim of this report is, by illustrating a case of clozapine-induced parotitis and reviewing the literature on the topic, to bring awareness of the occurrence of this potential adverse effect of clozapine treatment.

Case Presentation: Due to poor response to several adequate trials with different antipsychotic medications a 57-year-old female with schizoaffective disorder was initiated on clozapine in 2008. The psychiatric condition of the patient notably improved in the following years. In 2016, after a decrease in her psychotropic therapy, the patient was hospitalized, and while restoring treatment with clozapine and divalproex she complained of increased salivation combined with painful bilateral parotid enlargement. The diagnosis of clozapine-induced parotitis was suggested. The medical condition had a favorable outcome within five days after administration of symptomatic medication.

Conclusion: Adherence to drug treatment in psychiatric patients can be significantly improved if patients are well informed about the potential adverse effects of the administered medications and if the clinicians recognize and try to resolve them. Monitoring both common and rare adverse effects of clozapine treatment will give patients a chance of better therapy management.


Keywords

Clozapine, parotitis, adverse drug reactions

Full Text


References

Cheng F, Jones PB, Talbot PS. Antipsychotics. In: Anderson I, Hamish McAllister-Williams R, editors. Fundamentals of clinical psychopharmacology. 4th ed. Boca Raton, FL, USA: CRC Press; 2015. p. 47-76.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373 (9657):31-41.

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. doi: 10.1038/nrendo.2011.156.

Brooks KG, Thompson DF. A review and assessment of drug-induced parotitis. Ann Pharmacother. 2012; 46(12):1688-99. doi: 10.1345/aph.1R228.

Gershon A. Mumps. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 17th ed.. New York: McGrawHill; 2008. p. 1220-1.

De Fazio P, Gaetano R, Caroleo M, Cerminara G, Maida F, Bruno A, et al. Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat. 2015; 11:1995-2003. doi: 10.2147/NDT.S83989.

Arimone Y, Miremont-Salamé G, Haramburu F, Molimard M, Moore N, Fourrier-Réglat A, et al. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol. 2007;64(4):482-8. doi: 10.1111/j.1365-2125.2007.02937.x.

The use of the WHO–UMC system for standardised case causality assessment. Accessed from: http://www.WHO-UMC.org

Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Naidu RP. Causality assessment: A brief insight into practices in pharmaceutical industry. Perspect Clin Res. 2013; 4(4):233-6. doi: 10.4103/2229-3485.120173.

Martin SD. Drug-induced parotid swelling. Br J Hosp Med. 1993; 50(7):426.

Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. Am J Psychiatry. 1995;152(2):297–8. doi: 10.1176/ajp.152.2.297.

Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychaitry 1995; 56(11):511-3.

Dave M. Iatrogenic salivary gland swelling. J Pharm Technol. 1995;11:18–20.

Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis: an immunological cause? Am J Psychiatry. 1996;153(6):840.

Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry. 1996;153(3):445.

Patkar AA, Alexander RC. Parotid gland swelling with clozapine. J Clin Psychiatry. 1996;57(10):488.

Southhall K, Fernando N. Report of a rare medical complication on clozapine. Aust NZ J Psychiat. 1999;33(1):122–3. doi: 10.1080/0004867900029.

McKay D. Perhaps not so rare? Aust NZ J Psychiat. 2000;34:340–1.

Acosta-Armas AJ. Two cases of parotid gland swelling in patients taking clozapine. Hosp Med. 2001;62(11):704-5.

Immadisetty V, Agrawal P. A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review. Ther Adv Psychopharmacol. 2012; 2(6):235–39.

Vohra A. Clozapine- induced recurrent and transient parotid gland swelling. Afr J Psychiatry. 2013; 16(4):236-8.

Gouzien C, Valiamé A, Misdrahi, D. Clozapine-induced parotitis: a case study. L’encéphale. 2014; 40:81-5.

Saguem BN, Bouhlel S, Salem CB, Ben Hadj Ali B. Eosinophilia and parotitis occurring early in clozapine treatment. Int J Clin Pharm. 2015; 37:992-5.

Jerónimo J, Santos J, Bastos L. Uncommon effects of clozapine. Eur Psychiatry. 2016; 33:S614.




DOI: http://dx.doi.org/10.14748/ssm.v50i2.5011

Refbacks

About The Author

Koraliya Todorova-Nenova
Medical University of Varna, Bulgaria
Bulgaria

Department of Psychiatry and Medical  Psychology

Font Size


|